Galderma reported record net sales of $3.134 billion for H1 2026 and raised full-year guidance, cementing its position as the largest pure-play aesthetics company by revenue. The upgrade reflects robust demand across its portfolio—BOTOX, Restylane, Sculptra, and Radiesse—and signals confidence in sustained pricing power and volume growth through year-end.